Pharmacologic management of heart failure and left ventricular systolic dysfunction
Subtitle: effect in female, black, and diabetic patients, and cost-effectiveness
By: prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Southern California-RAND Evidence-based Practice Center, Santa Monica, CA ; program director, Paul Shekelle, program co-director, Sally Morton ... [et al.].
Contributors: Shekelle, Paul G.; Morton, Sally C.; Southern California Evidence-Based Practice Center/RAND.
Series: Evidence report/technology assessment -- no. 82; AHRQ publication -- no. 03-E045
Publisher: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality
Published: 2003
Place of publication: Rockville, Md
Language: eng
Number of pages: 163
Subjects: Heart failure -- Chemotherapy -- Evaluation; Heart failure -- Chemotherapy -- Cost effectiveness; Adrenergic beta blockers -- Therapeutic use -- Evaluation; Angiotensin converting enzyme -- Inhibitors -- Therapeutic use -- Evaluation; Diabetes -- Complications -- Chemotherapy -- Evaluation; Evidence-based medicine; Heart Failure -- drug therapy; Ventricular Dysfunction, Left -- drug therapy; Evidence-Based Medicine -- methods
Notes: "Prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services."

"July 2003."

"Contract no.: 290-97-0001."

""Bibliography": p. 101-128.

Includes bibliographical references (p. 83-85).